The PCROWD Study invites people with precursor conditions to Share samples a few times each year
NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
What is Myeloma? | Cancer Research UK 2021
PE: CRI - Cancer Research Institute: Cellular Therapies: TIL, TCR, CAR T, and NK Cell Therapies
NIH: Clinical Trials: Bringing Cancer Research to All Possible Participants
What are the different stages of Multiple Myeloma? REVISED - INTERNATIONAL STAGING SYSTEM (R-ISS)
Virtual Meeting: 2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021
clonoSEQ: Adaptive Biotechnologies - What is Minimal residual disease (MRD)?
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
Virtual Conference: Lymphoma, Leukemia & Myeloma Congress - October 19-23, 2021 New York
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
26th Annual International Congress on Hematologic Malignancies®: Leukemias, Lymphomas, and Myeloma
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5